The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

F McDermott, David; Cheng, Su-Chun; Signoretti, Sabina; A Margolin, Kim; I Clark, Joseph; A Sosman, Jeffrey; P Dutcher, Janice; F Logan, Theodore; D Curti, Brendan; S Ernstoff, Marc; Appleman, Leonard; K K Wong, Michael; I Khushalani, Nikhil; Oleksowicz, Leslie; N Vaishampayan, Ulka; W Mier, James; J Panka, David; S Bhatt, Rupal; S Bailey, Alexandra; C Leibovich, Bradley; D Kwon, Eugene; F Kabbinavar, Fairooz; S Belldegrun, Arie; A Figlin, Robert; J Pantuck, Allan; M Regan, Meredith; B Atkins, Michael

doi:10.1158/1078-0432.ccr-14-1520

Public

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

Shared by NobleBlocks on Feb 1, 2015 • 12:00 AM UTC

Authors:

David F McDermott

Su-Chun Cheng

Sabina Signoretti

Abstract

PURPOSE: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. Th...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!